Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Problem Tech Solves
Tech Brief
Genetics and genomics are important for many areas of medicine – oncology, cardiology, neurology, reproductive health, pediatrics and rare disease – where early identification for at-risk patients is crucial and where genomics can inform diagnosis and treatment. But clinical assessment guidelines are challenging to integrate into clinical practice and most physicians report they cannot keep up with the evolving standard of care. This results in fewer than one in five patients who meet genetic testing guidelines being appropriately identified. Without this early knowledge, these patients may not benefit from potentially life-saving intervention and treatment. We provide physicians with the tools to assess patients for hereditary risks. We then counsel patients, order testing when appropriate and deliver recommended care plans back to the provider and patient. Created by genetic specialists, our RISE Risk Assessment Module: Hereditary Cancer collects and analyzes family and personal health history to determine if a patient meets genetic testing criteria and then schedules a genetic counseling appointment if needed. The RISE patient completion rate is 95%, and on average, 23% of patients screened have met NCCN guidelines, demonstrating they may benefit from genetic services. Providers can point their patients to RISE for a guidelines-based process that improves compliance, saves physician time and improves patient screening. For example, one OB/GYN practice offering RISE has screened more than 1,000 women in six months with a 96% completion rate. Of those, 18% have been identified as meeting genetic testing criteria, and 40% have scheduled an appointment with a genetic counselor.
Tech Differentiators
Genome Medical is unique in that it is a nationwide telehealth specialty medical group delivering genetics and genomics-based care to patients everywhere. Simply put, we break down barriers and remedy disparities in access for patients all around the country so they can benefit from standard-of-care genomics and access these advancements. We also help providers overcome their own knowledge barriers in understanding how to adopt appropriate genomics care for the benefit of patients. We offer an unmatched combination of comprehensive clinical expertise and rapid technological innovation. We are the only virtual medical group delivering end-to-end genomics care across all 50 states. Our specialists – including medical geneticists, genetic counselors, primary care physicians, pharmacists, oncologists and other specialists – provide virtual genetics care across every major area of clinical care. Even in specialties like pediatric genetics that have a short supply of providers and extensive wait times, Genome Medical is able to use virtual care delivery to connect our team with physicians and patients in need of life-changing support. We are a clinical partner that integrates into clinical workflows; collaborates in real time with clinicians to provide medical guidance; and ensures test results lead to clear and actionable clinical plans. The delivery of genetic health services through Genome Medical is reliably efficient – we can remove 50%-75% of the cost of traditional services and increase genetic counseling capacity by over 80%. Our innovative SaaS modules scale rapidly to support day-to-day health care management with genomics.
Validation
Genome Medical estimates ROI on the value of the services we provide directly and the economic impact from the benefit of changing care for these patients. We deliver a 5X return on the cost of our services by eliminating waste, reducing inappropriate utilization and steering to in-network labs. We have also modeled downstream revenue based on published literature, claims data and other sources, which has allowed us to develop reasonable estimates for a cancer center and a women’s health model. In order to further validate our models, we are now actively working with partner sites to collect and analyze real world data. In our women’s health model, we took a conservative approach and examined a limited panel of genes. This example illustrates the downstream revenue that a health system will generate if hereditary breast and ovarian cancer (HBOC) screening – limited to BRCA1/2 genes – is offered to a broad population of women as appropriate. Our data predicts that for every 10,000 women screened for risk of HBOC we estimate an annual downstream revenue of approximately $1.6 million. This grows to $7.9 million in the first five years. Additionally, by detecting cancer at an early stage, mortality is significantly decreased and the cost of care is lowered by 68% (based on 5-year survival data from SEER Cancer Statistics Review, National Cancer Institute. Additional citation information available).
